FATE THERAPEUTICS INC's ticker is FATE and the CUSIP is 31189P102. A total of 169 filers reported holding FATE THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 9.78 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $652,175 | -74.4% | 307,630 | -42.6% | 0.00% | – |
| Q2 2023 | $2,550,713 | -64.7% | 535,864 | -57.7% | 0.00% | – |
| Q1 2023 | $7,217,648 | +13.7% | 1,266,254 | +101.2% | 0.00% | -100.0% |
| Q4 2022 | $6,349,268 | -80.6% | 629,264 | -57.0% | 0.00% | -66.7% |
| Q3 2022 | $32,764,000 | -6.5% | 1,462,065 | +3.4% | 0.00% | 0.0% |
| Q2 2022 | $35,035,000 | -44.1% | 1,413,859 | -12.5% | 0.00% | -40.0% |
| Q1 2022 | $62,641,000 | -39.8% | 1,615,716 | -9.1% | 0.01% | -37.5% |
| Q4 2021 | $103,992,000 | -22.0% | 1,777,329 | -21.0% | 0.01% | -27.3% |
| Q3 2021 | $133,325,000 | -76.2% | 2,249,450 | -65.1% | 0.01% | -75.0% |
| Q2 2021 | $559,876,000 | -18.5% | 6,450,927 | -22.5% | 0.04% | -25.4% |
| Q1 2021 | $686,701,000 | -0.7% | 8,328,701 | +9.5% | 0.06% | -4.8% |
| Q4 2020 | $691,514,000 | +148.2% | 7,604,904 | +9.1% | 0.06% | +121.4% |
| Q3 2020 | $278,654,000 | +28.2% | 6,971,568 | +10.0% | 0.03% | +16.7% |
| Q2 2020 | $217,423,000 | +42.3% | 6,337,023 | -7.9% | 0.02% | +14.3% |
| Q1 2020 | $152,842,000 | +13.4% | 6,881,683 | -0.1% | 0.02% | +40.0% |
| Q4 2019 | $134,751,000 | +26.2% | 6,885,583 | +0.1% | 0.02% | +15.4% |
| Q3 2019 | $106,795,000 | -23.5% | 6,876,683 | +0.1% | 0.01% | -18.8% |
| Q2 2019 | $139,515,000 | +12.7% | 6,872,683 | -2.5% | 0.02% | +6.7% |
| Q1 2019 | $123,846,000 | +30.8% | 7,048,702 | -4.5% | 0.02% | +15.4% |
| Q4 2018 | $94,689,000 | -23.9% | 7,380,302 | -3.4% | 0.01% | -7.1% |
| Q3 2018 | $124,413,000 | +65.6% | 7,637,402 | +15.3% | 0.01% | +55.6% |
| Q2 2018 | $75,137,000 | -2.7% | 6,625,806 | -16.3% | 0.01% | 0.0% |
| Q1 2018 | $77,258,000 | +60.8% | 7,915,808 | +0.7% | 0.01% | +50.0% |
| Q4 2017 | $48,035,000 | +205.5% | 7,861,643 | +98.0% | 0.01% | +200.0% |
| Q3 2017 | $15,724,000 | +11.6% | 3,970,785 | -8.7% | 0.00% | 0.0% |
| Q2 2017 | $14,084,000 | -29.5% | 4,346,785 | -1.0% | 0.00% | -33.3% |
| Q1 2017 | $19,983,000 | +81.3% | 4,391,885 | 0.0% | 0.00% | +200.0% |
| Q4 2016 | $11,024,000 | -18.0% | 4,391,885 | +2.0% | 0.00% | -50.0% |
| Q3 2016 | $13,439,000 | +83.5% | 4,307,485 | 0.0% | 0.00% | +100.0% |
| Q2 2016 | $7,323,000 | -5.5% | 4,307,485 | 0.0% | 0.00% | 0.0% |
| Q1 2016 | $7,753,000 | -46.6% | 4,307,485 | 0.0% | 0.00% | -50.0% |
| Q4 2015 | $14,516,000 | -36.7% | 4,307,485 | +0.1% | 0.00% | -33.3% |
| Q3 2015 | $22,941,000 | -12.5% | 4,304,186 | +6.2% | 0.00% | 0.0% |
| Q2 2015 | $26,216,000 | +73.2% | 4,051,858 | +30.9% | 0.00% | +50.0% |
| Q1 2015 | $15,137,000 | -2.4% | 3,095,582 | +0.4% | 0.00% | 0.0% |
| Q4 2014 | $15,514,000 | -1.9% | 3,084,373 | +0.3% | 0.00% | 0.0% |
| Q3 2014 | $15,814,000 | -17.9% | 3,076,573 | +0.8% | 0.00% | -33.3% |
| Q2 2014 | $19,268,000 | -35.2% | 3,053,573 | -0.0% | 0.00% | -25.0% |
| Q1 2014 | $29,743,000 | – | 3,053,673 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Polaris Venture Management Co. V, L.L.C. | 569,889 | $51,820,000 | 67.63% |
| Johnson & Johnson Innovation - JJDC, Inc. | 3,379,064 | $307,258,000 | 39.62% |
| Darwin Global Management, Ltd. | 952,847 | $86,642,000 | 24.18% |
| Redmile Group, LLC | 12,629,737 | $1,148,422,000 | 13.91% |
| DAFNA Capital Management LLC | 334,360 | $30,403,000 | 9.05% |
| Casdin Capital, LLC | 3,050,000 | $277,337,000 | 8.22% |
| Grosvenor Holdings, L.L.C. | 1,459,517 | $132,714,000 | 7.23% |
| Copernicus Capital Management, LLC | 3,240 | $295,000 | 4.60% |
| Eversept Partners, LP | 399,499 | $36,326,444 | 4.26% |
| Ally Bridge Group (NY) LLC | 260,000 | $23,642,000 | 4.05% |